Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Operations: 2014-2025

Historic Cash from Operations for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$15.5 million.

  • CytomX Therapeutics' Cash from Operations rose 24.99% to -$15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.3 million, marking a year-over-year increase of 18.16%. This contributed to the annual value of -$86.2 million for FY2024, which is 53.89% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Cash from Operations of -$15.5 million as of Q3 2025, which was up 1.30% from -$15.8 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Cash from Operations high stood at $9.3 million for Q1 2023, and its period low was -$41.3 million during Q1 2022.
  • Over the past 3 years, CytomX Therapeutics' median Cash from Operations value was -$19.9 million (recorded in 2024), while the average stood at -$17.7 million.
  • The largest annual percentage gain for CytomX Therapeutics' Cash from Operations in the last 5 years was 122.63% (2023), contrasted with its biggest fall of 1,476.67% (2023).
  • CytomX Therapeutics' Cash from Operations (Quarterly) stood at -$31.2 million in 2021, then spiked by 95.53% to -$1.4 million in 2022, then slumped by 1,476.67% to -$22.0 million in 2023, then rose by 9.36% to -$19.9 million in 2024, then rose by 24.99% to -$15.5 million in 2025.
  • Its last three reported values are -$15.5 million in Q3 2025, -$15.8 million for Q2 2025, and -$21.0 million during Q1 2025.